EA201890170A1 - Композиции и способы, связанные с захватывающими частицами - Google Patents
Композиции и способы, связанные с захватывающими частицамиInfo
- Publication number
- EA201890170A1 EA201890170A1 EA201890170A EA201890170A EA201890170A1 EA 201890170 A1 EA201890170 A1 EA 201890170A1 EA 201890170 A EA201890170 A EA 201890170A EA 201890170 A EA201890170 A EA 201890170A EA 201890170 A1 EA201890170 A1 EA 201890170A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- methods associated
- capturing particles
- pathogen
- inhibit
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 2
- 244000052769 pathogen Species 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
Abstract
Изобретение представляет, помимо прочего, композиции, которые связываются с растворимыми биомолекулами и ингибируют их биологическую активность, а также фармацевтические композиции. Композиции могут содержать множество частиц, которые специфически связываются с мишенью, такой как растворимая биомолекула или биомолекула на поверхности патогена, для ингибирования способности мишени (или патогена) взаимодействовать с другими молекулами или клетками. Кроме того, в данном документе представлен ряд применений (например, терапевтических применений), где композиции являются полезными.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186838P | 2015-06-30 | 2015-06-30 | |
US201562198541P | 2015-07-29 | 2015-07-29 | |
US201562198519P | 2015-07-29 | 2015-07-29 | |
US201562236507P | 2015-10-02 | 2015-10-02 | |
US201662319092P | 2016-04-06 | 2016-04-06 | |
PCT/US2016/040022 WO2017004159A1 (en) | 2015-06-30 | 2016-06-29 | Compositions and methods related to scavanger particles |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890170A1 true EA201890170A1 (ru) | 2018-07-31 |
Family
ID=57609422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890170A EA201890170A1 (ru) | 2015-06-30 | 2016-06-29 | Композиции и способы, связанные с захватывающими частицами |
Country Status (15)
Country | Link |
---|---|
US (1) | US20180256747A1 (ru) |
EP (1) | EP3316864A4 (ru) |
JP (3) | JP7370691B2 (ru) |
KR (1) | KR20180043785A (ru) |
CN (4) | CN116763941A (ru) |
AU (2) | AU2016285868B2 (ru) |
BR (1) | BR112017028315A2 (ru) |
CA (1) | CA2991142A1 (ru) |
EA (1) | EA201890170A1 (ru) |
HK (1) | HK1255328A1 (ru) |
IL (2) | IL256445B2 (ru) |
MX (3) | MX2017017051A (ru) |
MY (1) | MY198240A (ru) |
SG (1) | SG10201913518XA (ru) |
WO (1) | WO2017004159A1 (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA035898B1 (ru) | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Композиции и способы для ингибирования биологической активности растворимых биомолекул |
CN116999396A (zh) * | 2015-07-29 | 2023-11-07 | 纳米提克斯有限责任公司 | 用于清除可溶性生物分子的模块化组合物及其相关方法 |
WO2017136356A2 (en) * | 2016-02-01 | 2017-08-10 | Emory University | Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
EP3463416A1 (en) | 2016-05-31 | 2019-04-10 | CardioVax, LLC | Methods for diagnosing and treating systemic lupus erythematosus |
IL299915A (en) * | 2017-01-04 | 2023-03-01 | Nanotics Llc | Methods for assembling cleaning particles |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN113893328A (zh) * | 2017-06-14 | 2022-01-07 | 天津医科大学总医院 | 一种人源乳凝集素亚型蛋白的新用途 |
EP3477305A1 (en) | 2017-10-25 | 2019-05-01 | Universität Heidelberg | Delta-like ligand 1 for diagnosing severe infections |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
FR3094268B1 (fr) * | 2019-03-28 | 2021-03-19 | Carbiolice | Article multicouche enzymé |
CA3130033A1 (en) | 2019-04-15 | 2020-10-22 | Nanologica Ab | Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
CA3144267A1 (en) * | 2019-06-21 | 2020-12-24 | Entelexo Biotherapeutics Inc. | Platforms, compositions, and methods for therapeutics delivery |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
WO2021231436A1 (en) * | 2020-05-11 | 2021-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic methods for treating covid-19 infections |
CN111575388B (zh) * | 2020-06-02 | 2022-10-21 | 江汉大学 | PfHMGB1作为藻毒素侵害的分子标志物的应用及检测试剂盒 |
CN112264115B (zh) * | 2020-10-26 | 2022-03-11 | 南京鼓楼医院 | 一种搭载分子印迹反蛋白石结构微球的鱼骨微流控芯片及其制备方法 |
CN113358617B (zh) * | 2021-06-02 | 2024-03-01 | 重庆大学 | 胞外囊泡富集检测方法 |
KR20230023442A (ko) | 2021-08-10 | 2023-02-17 | 현대자동차주식회사 | 차량의 차체 |
CN114128723B (zh) * | 2021-11-09 | 2023-07-04 | 苏州大学 | 一种抗病毒纳米材料及其应用 |
JP7368766B2 (ja) | 2022-03-02 | 2023-10-25 | 株式会社リコー | 情報処理装置、情報処理システム、情報処理方法およびプログラム |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144252A1 (de) * | 2001-08-31 | 2003-03-27 | Fraunhofer Ges Forschung | Nanopartikel mit daran immobilisiertem biologisch aktivem TNF |
CN101123990A (zh) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒,和免疫原性结构 |
US20070248680A1 (en) * | 2005-02-08 | 2007-10-25 | Board Of Regents, The University Of Texas System | Particles for Inactivating Toxins |
EP2033660A1 (en) * | 2007-09-05 | 2009-03-11 | Freie Universität Berlin | Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
US9333163B2 (en) * | 2008-10-06 | 2016-05-10 | Massachusetts Institute Of Technology | Particles with multiple functionalized surface domains |
US20120108787A1 (en) * | 2009-02-26 | 2012-05-03 | Nubiome, Inc. | Immobilization Particles for Removal of Microorganisms and/or Chemicals |
EP3412282A1 (en) * | 2011-06-02 | 2018-12-12 | The Regents of the University of California | Membrane encapsulated nanoparticles and method of use |
US20140341975A1 (en) * | 2011-08-26 | 2014-11-20 | Vicoy Nanomedicines Ltd | Pathogen and substance traps |
WO2014109842A2 (en) * | 2012-11-28 | 2014-07-17 | Cytimmune Sciences, Inc. | Nanotechnology based medicine for biodefense |
WO2015112842A1 (en) * | 2014-01-24 | 2015-07-30 | Ntercept, Llc | Methods and compositions for immune dis-inhibition |
EA035898B1 (ru) * | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Композиции и способы для ингибирования биологической активности растворимых биомолекул |
-
2016
- 2016-06-29 EA EA201890170A patent/EA201890170A1/ru unknown
- 2016-06-29 IL IL256445A patent/IL256445B2/en unknown
- 2016-06-29 CA CA2991142A patent/CA2991142A1/en active Pending
- 2016-06-29 CN CN202310869623.1A patent/CN116763941A/zh active Pending
- 2016-06-29 CN CN202111385729.1A patent/CN114129737A/zh active Pending
- 2016-06-29 EP EP16818651.8A patent/EP3316864A4/en active Pending
- 2016-06-29 BR BR112017028315A patent/BR112017028315A2/pt active Search and Examination
- 2016-06-29 SG SG10201913518XA patent/SG10201913518XA/en unknown
- 2016-06-29 US US15/738,954 patent/US20180256747A1/en active Pending
- 2016-06-29 KR KR1020187002793A patent/KR20180043785A/ko not_active Application Discontinuation
- 2016-06-29 CN CN202310865497.2A patent/CN116785457A/zh active Pending
- 2016-06-29 IL IL297460A patent/IL297460A/en unknown
- 2016-06-29 JP JP2017568165A patent/JP7370691B2/ja active Active
- 2016-06-29 AU AU2016285868A patent/AU2016285868B2/en active Active
- 2016-06-29 CN CN201680049849.5A patent/CN108135848A/zh active Pending
- 2016-06-29 MY MYPI2017001935A patent/MY198240A/en unknown
- 2016-06-29 MX MX2017017051A patent/MX2017017051A/es unknown
- 2016-06-29 WO PCT/US2016/040022 patent/WO2017004159A1/en active Application Filing
-
2017
- 2017-12-20 MX MX2023005261A patent/MX2023005261A/es unknown
- 2017-12-20 MX MX2023005262A patent/MX2023005262A/es unknown
-
2018
- 2018-11-13 HK HK18114464.8A patent/HK1255328A1/zh unknown
-
2021
- 2021-10-29 JP JP2021177516A patent/JP2022031665A/ja not_active Withdrawn
-
2022
- 2022-01-14 AU AU2022200233A patent/AU2022200233B2/en active Active
-
2023
- 2023-07-13 JP JP2023114971A patent/JP2023153813A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL256445B (en) | 2022-11-01 |
WO2017004159A1 (en) | 2017-01-05 |
AU2022200233B2 (en) | 2024-05-30 |
JP2018524344A (ja) | 2018-08-30 |
IL256445A (en) | 2018-04-30 |
HK1255328A1 (zh) | 2019-08-16 |
IL256445B2 (en) | 2023-03-01 |
IL297460A (en) | 2022-12-01 |
CN108135848A (zh) | 2018-06-08 |
JP2022031665A (ja) | 2022-02-22 |
EP3316864A1 (en) | 2018-05-09 |
CA2991142A1 (en) | 2017-01-05 |
CN116785457A (zh) | 2023-09-22 |
SG10201913518XA (en) | 2020-02-27 |
AU2016285868A1 (en) | 2018-02-01 |
KR20180043785A (ko) | 2018-04-30 |
JP2023153813A (ja) | 2023-10-18 |
CN116763941A (zh) | 2023-09-19 |
MY198240A (en) | 2023-08-16 |
MX2023005262A (es) | 2023-05-23 |
US20180256747A1 (en) | 2018-09-13 |
AU2022200233A1 (en) | 2022-02-10 |
CN114129737A (zh) | 2022-03-04 |
JP7370691B2 (ja) | 2023-10-30 |
AU2016285868B2 (en) | 2021-11-11 |
MX2023005261A (es) | 2023-05-23 |
EP3316864A4 (en) | 2019-03-06 |
MX2017017051A (es) | 2018-05-15 |
BR112017028315A2 (pt) | 2018-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890170A1 (ru) | Композиции и способы, связанные с захватывающими частицами | |
EA201890391A1 (ru) | Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
EA201890630A1 (ru) | Антитела против pd-1 и способы их применения | |
EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
PH12018501778A1 (en) | Antibodies to tigit | |
PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
MY181106A (en) | Anti-lag3 antibodies and uses thereof | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
MX2020010530A (es) | Anticuerpos humanizados contra cd269 (bcma). | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
EA201890619A1 (ru) | КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
WO2015112805A8 (en) | Human antibodies to pd-l1 | |
EA201691488A1 (ru) | Молекулы антител против pd-1 и их применения | |
BR112016029123A2 (pt) | tratamento de linfomas | |
EA201890079A1 (ru) | Клеточная система для направленной доставки активного ингредиента | |
EA201591103A1 (ru) | Полоксамеры с удлиненной цепью, получаемые из них термообратимые гидрогели, содержащие биологические вещества, и их применение в медицине | |
EA201790773A1 (ru) | Композиции и способы для ингибирования биологической активности растворимых биомолекул | |
AR108180A1 (es) | Partículas que comprenden subpartículas o estructuras de ácidos nucleicos | |
EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
EA201990884A1 (ru) | АНТИ-C1s АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
EA201892440A1 (ru) | Антитела к tl1a и их применения | |
EA201491724A1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения |